



## Tumour Associated Dendritic Cells

Guest Editor:

**A/Prof. Dr. Kristen Radford**

Mater Research Institute, The  
University of Queensland,  
Translational Research Institute,  
Woolloongabba, QLD 4102,  
Australia

Deadline for manuscript  
submissions:

**closed (28 February 2019)**

### Message from the Guest Editor

The key role of dendritic cells (DC) in priming adaptive immune responses has long been harnessed for cancer vaccines. Although there is clear evidence that DC vaccines are well tolerated and can induce tumour immune responses, overall they have been of limited clinical benefit. Despite their long history in the clinic, the role of DC in tumour tissue is not well understood and has been confounded by their rarity, heterogeneity and overlapping markers with other myeloid populations. DC can be divided into distinct subsets with highly specialized functions. In a number of mouse tumour models the cDC1 DC subset has been shown to be required for priming anti-tumour immunity and for the efficacy of immunotherapies. These findings reinvigorate manipulation of DC as an attractive strategy to induce or improve immune responses in cancer patients. In this Special Issue, we welcome submissions that will help to build a more complete picture of the role of DC in cancer and particularly welcome submissions on the role of DC subsets in a variety of cancer types, human cancers and new ways in which they may be harnessed to improve tumour immune responses.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)